Списоклитературы

1. АржановаО.Н.,КузнецоваА.В.Лечениеплацентарнойнедостаточностиубеременныхсантифосфолипиднымсиндромомиварикознойболезнью.//

Consiliummedicum.-2006.-N8, №6.-C.28-30.

2. АфанасьеваН.В.,СтрижаковА.Н.Исходыбеременностииродовприфетоплацентарнойнедостаточностиразличнойстепенитяжести.Вопр.гинекол.,акушер.,перинатал. 2004;3(2):7-13.

3. БицадзеВ.О.Патогенез,принципыдиагностикиипрофилактикиосложненийбеременности,обусловленныхтромбофилией.Дис.…докт.мед.наук.-М.2004.-297с.

4ГеворкянМ.А.,МанухинИ.Б.«Клиническиелекциипогинекологической

эндокринологии».М.Гэотар-Медиа, 2006.–320с.

5. ДобрынинаЛ.А.,КалашниковаЛ.А.,ПавловаЛ.Н.Причиныишемическогоинсультавмолодомвозрасте.Журналневрологииипсихиатрииим.С.С.Корсакова.2011;3:4-8.

5. КалашниковаЛ.А.Цереброваскулярныенарушенияприантифосфолипидномсиндроме.Том5.N1,2011.

6. КалашниковаЛ.А.Неврологияантифосфолипидногосиндрома.М.:Медицина,2003,256с.:ил.

7. МакаровО.В.,ТкачевО.РН,ВолковаЕ.В.Преэклампсияихроническаяартериальнаягипертензия.Клиническиеаспекты.-М.:«Гэотар-Медиа»,2010.-136с.

8. МакаровИ.О.,СидороваИ.С.Современныйвзгляднапатогенезфетоплацентарнойнедостаточности//МатериалыVIIРоссфорумаМатьидитя.М., 2005-С.134

9. МакацарияА.Д.,БицадзеВ.О.,БаймурадоваС.М.,ДолгушинаН.В.,ЮдаеваЛ.С.,ХизроеваД.Х.,АкиньшинаС.В.«Антифосфолипидныйсиндром–иммуннаятромбофилиявакушерствеигинекологии».М.,

«Триада-Х»,2007–456с.

5. МакацарияА.Д.,БелобородоваЕ.В.,БицадзеВ.О.,БаймурадоваС.М.

«Гипергомоцистеинемияиосложнениябеременности».М.,Триада-Х,2005.–216с.

5. МакацарияА.Д.,МищенкоА.Л.,БицадзеВ.О.,МаровС.В.«Синдромдиссеминированноговнутрисосудистогосвертываниякровивакушерскойпрактике».М.,Триада-Х,2002.–496с.

6. МакацарияА.Д.,БицадзеВ.О.,АкиньшинаС.В.«Синдромсистемноговоспалительногоответавакушерстве».

7. МакацарияА.Д.,БицадзеВ.О.,АкиньшинаС.В.«Тромбозыитромбоэмболиивашерско-гинекологическойклинике».М.:ООО

«Медицинскоеинформационноеагентство»,2007.–1064с.

5. МакацарияА.Д.,БицадзеВ.О.«Тромбофилииипротивотромботическаятерапиявакушерскойпрактике».М.,Триада-Х,2003.–904с.

6. МакацарияА.Д.,БицадзеВ.О.«Тромбофилическиесостояниявакушерскойпрактике».Научноеиздание.– М.:«Руссо», 2001.–704с.

7. МхеидзеН.Э.Клиническоезначениевыявлениягенетическойиприобретеннойтромбофилииубеременныхспреждевременной

отслойкойнормальнорасположеннойплацентыванамнезе.Дис.…канд.мед.наук.-М.2006.-129с.

5. НасоновЕ.Л.Ревматология.Национальноеруководство.-М.:Гэотар-Медиа,2008.-737с.

6. НасоновЕ.Л.Антифосфолипидныйсиндром.Монография.-М.:Литтера, 2004.-440с.

7. СавельеваГ.М.,ШалинаР.И.,СичинаваЛ.Г.,ПанинаО.Б.,КурцерМ.А.

«Акушерство.Учебник».М.,Гэотар-Медиа,2008.–656с.

5. СеровВ.Н.Плацентарнаянедостаточность.//ТруднПац.2005.Т3-№2.

С.18-19.

5. Стрижаков А.Н.. Игнатко И.В.«Потеря беременности». М. ООО

«Медицинскоеинформационноеагентство»,2007.–224с.

5. AmengualO,AtsumiT,KhamashtaMA,TinahonesF,HughesGR.Autoantibodiesagainstoxidizedlow-densitylipoproteininantiphospholipidsyndrome.BrJRheumatol.1997;36:964–968.

6. ArnoutJ,MeijerP,andVermylenJ.LupusanticoagulanttestinginEurope:ananalysisofresultsfromthefirstEuropeanConcertedActiononThrombophilia

(ECAT)surveyusingplasmasspikedwithmonoclonalantibodiesagainsthumanbeta2-glycoproteinI.ThrombHaemost1999;81(6):929–934.

5. Arulkumaran S. Clinical obstetrics and gynaecology. Inherited

thrombophilias.//ElsevierCompany.–2003.–528p.

5. AshersonRA,PietteJ-C,CerveraR.Primary,secondary,seronegative,catastrophicandothersubsetsoftheantiphospholipidsyndrome.2002ElsivierScience.285-292.

6. AshersonSA:Newsubsetsoftheantiphospholipidsyndromein2006:'PRE-APS'(probableAPS)andmicroangipathicantiphospholipidsyndrome('MAPS').Autoimmun.Rev.6,76–80(2006).

7. AzemF,ManyI,YovelI,AmitA,LessingJB,KupfermincMJ.IncreasedratesofthrombophiliainwomenwithrepeatedIVFfailures.HumanReproductionVol.19,N2,pp.368-370,2004.

8. AtsumiT,KhamashtaMA,AmengualO,DonohoeS,MackieI,IchikawaK,KoikeT,HughesGR.BindingofanticardiolipinantibodiestoproteinCviaß2-glycoproteinI(ß2-GPI):apossiblemechanismintheinhibitoryeffectofantiphospholipidantibodiesontheproteinCsystem.ClinExpImmunol.1998;112:325–333.

9. AtsumiT,KhamashtaMA,HaworthRS,BrooksG,AmengualO,IchikawaK,

KoikeT,HughesGR.Arterialdiseaseandthrombosisintheantiphospholipidsyndrome:apathogenicroleforendothelin1.ArthritisRheum.1998;41:800–

807.

5. AtsumiT,IekoM,BertolacciniML,etal.Associationofautoantibodiesagainstthephosphatidylserine-prothrombincomplexwithmanifestationsoftheantiphospholipidsyndromeandwiththepresenceoflupusanticoagulant.ArthritisRheum2000;43(9):1982–1993.

6. AtsumiTandKoikeT.Antiprothrombinantibody:whydoweneedmoreassays?Lupus2010;19(4):436–439.

7. AudrainMA,El-KouriD,HamidouMA,etal.Valueofautoantibodiestobeta(2)-glycoprotein1inthediagnosisofantiphospholipidsyndrome.Rheumatology(Oxford)2002;41(5):550–553.

8. alenA.H.etal.Polycysticovarysyndrome.LondonandNewYork,

“Taylor&Francis”,2005.–256p.

5. BancsiLF,vanderLindenIK,BertinaRM.ß2-GlycoproteinIdeficiencyandtheriskofthrombosis.ThrombHaemost.1992;67:649–653.

5. BatesSM.Pregnancy-associatedvenousthromboembolism:preventionandtreatment.SeminarsinHematology,Vol48,N4,October2011,pp271-284.

6. BellWN,AltonHG.Abrainextractasasubstituteforplateletsuspensionsinthethromboplastingenerationtest.Nature.1955;174:880–881.

7. BergremA,JacobsenEM,SkjeldestadFE,etal.(2010)Theassociationofantiphospholipidantibodieswithpregnancy-relatedfirsttimevenousthrombosis–apopulation-basedcase-controlstudy.ThrombRes125(5):e222–

e227.

5. BickR.L.Disordersofthrombosisandhemostasis.Clinicalandlaboratorypractice. //3^rdeditionbyLippincottWilliams&Wilkins.–2002.–446p.

6. BickR.L.Antiphospholipidsyndromeinpregnancy.Hematology/OncologyclinicsofNorthAmerica. //bySaundersCompany.-2008.–999-1203.

7. BlankM,FadenD,TincaniA,KopolovicJ,GoldbergI,GilburdB,AllegriF,BalestrieriG,ValesiniG,ShoenfeldY.Immunizationwithanticardiolipin

cofactor(ß-2-glycoproteinI)inducesexperimentalantiphospholipidsyndromeinnaivemice.JAutoimmun.1994;7:441–455.

5. BlankM,KrauseI,FridkinMetal.:Bacterialinductionofautoantibodiesto

^β2^{-glycoprotein-Iaccountsfortheinfectiousetiologyofantiphospholipidsyndrome.}J.Clin.Invest.109,797–804(2002).

5. BlicksteinI.ObstetricsandgynecologyclinicsofNorthAmerica.//-ThrombophiliaandWomen’shealth.–Sept2003. -Vol.33,N3.

6. BoffaM-C,PietteJ-C.Papersandabstractsfromthe9thInternationalSymposiumonAntiphospholipidAntibodies.Tours,France,September12–16,2000.JAutoimmun.2000;15:81–A95.

7. BoseP,BlackS,KadyrovM,WeissenbornU,NeulenJ,ReganL,Huppertz

B.Heparinandaspirinattenuateplacentalapoptosisinvitro:implicationsforearlypregnancyfailure.AmJObstetGynecolo2005;192:23-30.

5. BourneT.,CondousG.Handbookofearlypregnancycare.//InformaHealhcareLtd.–2006.–158p.

6. BowieWEJ,ThompsonJH,PascuzziCA,OwenGA.Thrombosisinsystemicerythematosusdespitecirculatinganticoagulants.JClinInvest.1963;62:416–

430.

5. BranchDW,KhamashtaMA.Antiphospholipidsyndrome.ObstetGynecol.

2003Jun;101(6):1333-44.

5. BrennerB.Haemostaticchangesinpregnancy.ThrombRes2004;114:409-14.

6. BrennerB,AharonA.SarigG.Antiphospholipidsyndrome,heritablethrombophiliaandearlypregnancyloss.TextbookofPericonceptionalMedicine.EditedbyNickSMacklon,IanAGreerandEricAPSteegers.CRCPress2008;349-356.

7. BreyRL,StallworthCL,McGlassonDL,etal.Antiphospholipidantibodiesandstrokeinyoungwomen.Stroke2002;33(10):2396–2400.

5. BuckinghamKL,StonePR,SmithJF,ChamleyLW.Antiphospholipidantibodiesinserumandfollicularfluid–isthereacorrelationwithIVFimplantationfailure?HumanReproductionVol.21,N3,pp.728-734,2006.

6. CampbellAL,PierangeliSS,WellhausenS,HarrisEN.Comparisonoftheeffectsofanticardiolipinantibodiesfrompatientswiththeantiphospholipidsyndromeandwithsyphilisonplateletactivationandaggregation.ThrombHaemost.1995;73:529–534.

7. CarmonaF,BalaschJ.Fetalandobstetricmanifestationsandinfertilityintheantiphospholipidsyndrome.In:AshersonRA,CerveraR,PietteJC,ShoenfeldY (eds).TheantiphospholipidSyndromeII:AutoimmuneThrombosis.

Amsterdam:Elsevier,2002,205-211.

5. CarpHJ,ShoenfeldY.Anti-phospholipidantibodiesandinfertility.ClinRevAllergyImmunol2007;32:159-161.

6. Cervera R., Balasch J. Bidirectional effects on autoimmunity and

reproduction.HumanReproductionUpdate.May,22,pp1-8,2008.

5. CerveraR,EspinosaG.Updateonthecatastrophicantiphospholipidsyndromeandthe“CAPSRegistry”.SeminarsinThrombosisandHemostasis.Vol.38,N4/2012;333-337.

6. CockrellE,EspinosaR,McCrae.AnnexinII:biologyandrelevancetotheantiphospholipidsyndrome. Lupus, October1,2008'17(10):944-952.

7. ConleyCL,HartmannRC.Ahemorrhagicdisordercausedbycirculatinganticoagulantinpatientswithdisseminatedlupuserythematosus.JClinInvest.1952;31:621.

8. CostaM,ColiaD.Treatinginfertilityinautoimmunepatients.Rheumatology2008;47:38-41.

9. CrowtherMA,JohnstonM,WeitzJ,GinsbergJS.FreeproteinSdeficiency

maybefoundinpatientswithantiphospholipidantibodieswhodonothavesystemiclupuserythematosus.ThrombHaemost.1996;76:689–691.

5. DayHM,ThiagarajanP,AhnC,etal.Autoantibodiestobeta2-glycoproteinIinsystemiclupuserythematosusandprimaryantiphospholipidantibodysyndrome:clinicalcorrelationsincomparisonwithotherantiphospholipid

antibodytests.JRheumatol1998;25(4):667–674

5. DayaS.Efficacyofprogesteronesupportforpregnancyinwomenwithrecurrentmiscarriage.Ameta-analysisofcontrolledtrials.Br.JObstetricsGynaecol. 1989Mar;96(3):275-80.

6. DiSimoneN,LuigiM,MarcoD:Pregnanciescomplicatedwithantiphospholipidsyndrome:thepathogenicmechanismofantiphospholipidantibodies,areviewoftheliterature.Ann.NYAcad.Sci.1108,505–514(2007).

7. DoddJM,AshwoodP,FlenadyV,Jenkins-ManningS,CincotteR.Asurveyofclinicianandpatientattitudestowardstheuseofprogesteroneforwomenatriskofpretermbirth.AustNZJObstetrGynaecol.2007Apr;47(2):106-9.

5. DonadiniMP,AgenoW.Unusualsitethrombosis.SeminarsinHematology,Vol48,October2011,pp264-270.

6. DonadiniMP,DentaniF,AgenoW.Splanchnicveinthrombosis:newriskfactorsandmanagement.ThrombosisResearch129, Suppl1(2012)S93-S96.

7. EsmonNL,SafaO,SmirnovMD,EsmonCT.AntiphospholipidantibodiesandtheproteinCpathway.JAutoimmun.2000;15:221–225.

8. EsmonCT,XuJ,LupuF.Innateimmunityandcoagulation.Journalof

ThrombosisandHaemostasis,2011;9(Suppl.1):182-188.

5. EspinosaG,TassiesD,ReverterJ-C.Hematologicalabnormalitiesintheantiphospholipidsyndrome.2002.Elsevier Science B.V.259-276.

6. EuropeanStrokeInitiativeRecommendationsforStrokeManagement–Update2003. CerebrovascDis2003;16:311-337.

7. FavaloroEJ,WongRCW.Theantiphospholipidsyndrome:diagnosis,pathogenesis,laboratorytesting,andmanagement.SeminarsinThrombosis

andHemostasis.Vol.38,N4/2012;299-304.

5. FavaloroEJ,WheatlandLetal.Internalqualitycontrolandexternalqualityassuranceintestingforantiphospholipidantibodies:partI–anticardiolipinandanti-b2-glycoproteinIantibodies.Seminarsinthrombosisandhemostasis.Volume 38,Number4/2012;390-403.

6. FeinsteinDI,RapaportSI.Acquiredinhibitorsofbloodcoagulation.In:Spaet

TH,ed.ProgressinHemostasisandThrombosis.Vol1.NewYork,NY:Grune

&Stratton;1972:75–95.

5. FionaLyall,M.Belfort.Pre-eclampsia:etiologyandclinicalpractice.//CambridgeUniversityPress.–2007.–548p.

6. FujimuraY,MatsumotoM,YagiH.Thromboticmicroangiopathy.InternMed.

2010;49(1):7-15.

5. FurukawaS.,FujitaT.,ShimbakuroM.etal.Increasedoxidativestressinobesityanditsimpactonmetabolicsyndrome.//TheJournalofClinicalInvestigation.–2004.–Vol.114. -N.12.–P.1752–1761.

6. GabrielR.deFreitas,BogousslavskyJ.Riskfactorsofcerebralveinandsinus

thrombosis. Handbook on Cerebral Venous Thrombosis. Front NeurolNeurosci. Basel,Karger,2008,vol23, pp.23-54.

5. GalliM,ComfuriusP,MaassenC,etal.(1990)Anticardiolipinantibodies

(ACA)directednottocardiolipinbuttoaplasmaproteincofactor.Lancet335(8705):1544–1547.

5. GalliM.Interpretationandrecommendedtestingforantiphospholipidantibodies.SeminarsinThrombosisandHemostasis.Vol.38,N4/2012;348-352.

6. GharaviAE,Vega-OstertagM,EspinolaRGetal.:Intrauterinefetaldeathin

micecausedbycytomegalovirus-derivedpeptideinducedaPLantibodies.

Lupus13, 17–23(2004).

5. GilhamJC,MyersJE,BakerPN,TaggartMJ.TNF-αaltersnitricoxide–andendothelium-derivedhyperpolarizingfactor-mediatedvasodilatationinhuman

omentalarteries. HypertensioninPregnancy,27:29-38,2008.

5. SeminarsinThrombosisandHemostasis.Vol.38,N4/2012;328-332.

6. GinsbergJS,GreerI,HirshJ:Useofantithromboticagentsduringpregnancy.

Chest119(Suppl.1),S122–S131(2001).

5. GirardiG,BermanJ,RedechaP,SpruceL,ThurmanJMetal.ComplementC5areceptorsandneutrophilsmediatefetalinjuryintheantiphospholipidsyndrome.JClinInvest2003;112:1644-1654.

6. GirardiG,RedechaP,SalmonJ.Heparinpreventsantiphospholipidantibody-inducedfetallossbyinhibitingcomplementactivation.NatMed2004;10:1222.

7. Greinacher A, Eichler P, Lietz T, Warkentin TE. Replacement of

unfractionatedheparinbylow-molecular-weightheparinforpostorthopedicsurgeryantithromboticprophylaxislowerstheoverallriskofsymptomaticthrombosisbecauseofalowerfrequencyofheparin-inducedthrombocytopenia.Blood2005;106:2921-2.

5. GrootPhG,UrbanusRT.Thefutureofantiphospholipidantibodytesting.

Seminarsinthrombosisandhemostasis.Volume 38,Number 4/2012;412-419.

5. GushikenFC,ArnettFC,ThiagarajanP.Primaryantiphospholipidantibodysyndromewithmutationsinthephospholipidbindingdomainofß2-glycoproteinI.AmJHematol.2000;65:160–165.

6. IorioA.,BarnesC.,VedovatiM-C.Thrombophiliaandcerebralveinthrombosis.HandbookonCerebralVenousThrombosis.FrontNeurolNeurosci. Basel,Karger,2008,vol23, pp.55-76.

7. HameedA,ReganL.Acquiredthrombophiliaandrecurrentearlypregnancy

loss.In:EarlyPregnancy,ed.RoyG.FarquharsonandMaryD.Stephenson.PublishedbyCambridgeUniversityPress.2010.113-129.

5. HarrisEN,GharaviAE,BoeyML,PatelBM,MackworthYoungCG,LoizouS,HughesGR.Anticardiolipinantibodies:detectionbyradioimmunoassayand

associationwiththrombosisinsystemiclupuserythematosus.Lancet.1983;2:1211–1214.

5. HarrisEN,GharaviAE,BoeyML,etal.(1983)Anticardiolipinantibodies:

detectionbyradioimmunoassayandassociationwiththrombosisinsystemiclupuserythematosus.Lancet2(8361):1211–1214.Medline.

5. HarrisEN,HughesGRV,GharaviAE.Antiphospholipidantibodies:anelderlystatesmandonsnewgarments.JRheumatol.1987;14(suppl13): 208–213.

6. HellanM,KuhnelE,SpeiserW,LechnerK,EichingerS.Familiallupusanticoagulant.acasereportandreviewoftheliterature.BloodCoagulFibrinolysis.1998;9: 195–200.

5. HolersVM,GirardiG,MoL,GurthtidgeJM,MolinaH,PierangeliSS,EspinolaR,XiaoweiLEetal.C3activationisrequiredforanti-phospholipidantibody-inducedfetalloss.JExpMed2002;195:211-220.

6. HowardJA CARP.Recurrentpregnancyloss:causes,controversiesandtreatment.//InformaUK Ltd.–2007.–290p.

7. HughesGR.Theanticardiolipinsyndrome.ClinExpRheumatol.1985;3:285–286.

8. HughesGR,AshersonRA,andKhamashtaMA(1989)Antiphospholipidsyndrome:linkingmanyspecialties.AnnRheumDis48(5):355–356.

9. HughesGR,KhamashtaMA,GharaviAE,WilsonWA.NewOrleans7th

InternationalSymposiumonAntiphospholipidAntibodies.Proceedingsandabstracts.Lupus.1996;5:343–558.

5. HughesGRV,KhamashtaMA.Seronegativeantiphospholipidsyndrome.

AnnRheumDis2003;62:1127.

5. KaulK,ErkanD,Artim-EsenB,Diz-KucukkayaR,InancM,LockshinMD:Warfarinalternativesforsecondarythrombosisprophylaxisinantiphospholipidsyndrome.ArthritisRheum.52,S595(2005)(Abstract).

6. KenetG,AronisS,BerkunY,BonduelM.etal.Impactofpersistentantiphospholipidantibodiesonriskofincidentsymptomaticthromboembolisminchildren:asystematicreviewandmeta-analysis.Seminarsinthrombosisand

hemostasis.Volume 37,Number 7, 2012;802-809.

5. KershawG,SureshS,OrellanaD,NguyY-M.Laboratoryidentificationoflupusanticoagulants.Seminarsinthrombosisandhemostasis.Volume38,Number4/2012;375-384.

6. KhamashtaMA.Systemiclupuserythrematosusandpregnancy.BestPractResClinRheumatol2006;20:685-94.

7. KrikunG,LockwoodCJ,WuXX,ZhouXD,GullerS,CalandriC,GuhaA,NemersonY,RandJH.Theexpressionoftheplacentalanticoagulantprotein,annexinV,byvilloustrophoblasts:immunolocalizationandinvitroregulation.Placenta.1994;15:601–612.

8. KornbergA,RenaudineauY,BlankM,YouinouP,ShoenfeldY.Anti-ß2-

glycoproteinIantibodiesandanti-endothelialcellantibodiesinducetissuefactorinendothelialcells.IsrMedAssocJ.2000;2(suppl1):27–31.

5. KujovichJ.L.Thrombophiliaandpregnancycomplications.//AmericanJournalofObstetricsandGynecology.-2004.-191, 412-24.

6. LakosG,FavaloroEJ,HarrisEN,etal.Internationalconsensusguidelinesonanticardiolipinandanti-beta2-glycoproteinitesting:areportfromtheAPLTaskForceatthe13thInternationalCongressonAntiphospholipidAntibodies.ArthritisRheum2012;64(1):1–10.

7. LakosG.Interferenceinantiphospholipidantibody.SeminarsinThrombosisandHemostasis.Vol.38,N4/2012;353-359.

5. deLaatB,PengoV,PabingerI,etal.(2009)TheassociationbetweencirculatingantibodiesagainstdomainIofbeta2-glycoproteinIandthrombosis:aninternationalmulticenterstudy.JThrombHaemost7(11):1767–1773.

6. LaurellA,NilssonI.Hypergammaglobulinemia,circulatinganticoagulantandbiologicfalse-positiveWassermannreaction.JLabClinMed.1957;49:694–707.

7. LaskowskaM,LaskowskaK,OleszczukJ.Interleukin-18concentrationsin

pregnanciescomplicatedbypreeclampsiawithandwithoutIUGR:acomparisonwithnormotensivepregnantwomenwithisolatedIUGRandhealthypregnantwomen.PregnancyHypertension:AnInternationalJournalofWomen'sCardiovascularHealth1(2011);206-212.

5. LefkouE,HuntB.Pre-eclampsia.TheObstetricHematologyManual,ed.

SuePavordandBeverlyHunt.2010;203-217.

5. LelloucheF,MartinuzzoM,SaidP,MacloufJ,CarrerasLO.Imbalanceofthromboxane/prostacyclinbiosynthesisinpatientswithlupusanticoagulant.Blood.1991;78:2894–2899.

6. LevenoI.,KennethJ.Williamsmanualofobstetrics:pregnancycomplications.22-endedition.2007.–598p.

7. LeviM,NieuwdorpM,PollT,StroesE.MetabolicModulationofinflammation–inducedactivationofcoagulation.SeminarsinThrombosisand

Hemostasis/Vol34,Number 1;2008:26-32.

5. LesI,Ruiz-IrastorzaG,KhamashtaMA.Intensityanddurationofanticoagulationtherapyinantiphospholipidsyndrome.SeminarsinThrombosisandHemostasis.Vol.38,N4/2012;339-347.

6. LiebyP,PoindronV,RoussiS.Etal.Pathogenicantiphospholipidantibody:an antigen-selectedneedleinhaystack.Blood,September15,2004;

104(6):1711-1715.

5. deLignieresB.,DennersteinL.,BackstromT.Influenceofrouteofadministrationonprogesteronemetabolism.Maturitas.1995Apr.;21(3):251-

7.

5. LinWS,ChenPC,YangCDetal.:Someantiphospholipidantibodies^{recognizeconformationalepitopessharedbyβ}2^{-glycoproteinIandthehomologous}catalyticdomainsofseveralserineproteases.ArthritisRheum.56,1638–1647(2007).

6. LockshinMD,KimM,LaskinCA,etal.Lupusanticoagulant,butnotanticardiolipinantibody,predictsadversepregnancyoutcomeinpatientswithantiphospholipidantibodies.ArthritisRheum2012;64(7):2311–2318.

7. LockwoodCJ,HuangSJ,KrikunGetal.Decidualhemostasis,inflammation

and angiogenesis in preeclampsia. Seminars in Thrombosis andHemostasis/Vol37,Number 2. 2011:158-163.

5. LopezLR,DierKJ,LopezD,MerrillJT,andFinkCA.Anti-beta2-

glycoproteinIandantiphosphatidylserineantibodiesarepredictorsofarterial

thrombosisinpatientswithantiphospholipidsyndrome.AmJClinPathol2004;121(1):142–149.

5. LuongT-H,RandJH,WuXX,GodboldJH,Gascon-LemaMG,TuhrimS.Seasonaldistributionofantiphospholipidantibodies.Stroke.2001;32:1707–

1711.

5. LuotoR,KharazamiE,WhitleyEetal.Systolichypertensioninpregnancyandcardiovascularmortality:a44-yearfollow-upstudy.HypertensioninPregnancy,27:87-94,2008.

6. LydenTW,VogtE,NgAK,JohnsonPM,RoteNS.Monoclonalantiphospholipidantibodyreactivityagainsthumanplacentaltrophoblast.J

ReprodImmunol.1992;22:1–14.

5. LyleC.A.,BernardT.J.,GoldenbergN.A.Childhoodarterialischemicstroke:areviewofetiologies,antithrombotictreatments,prognosticfactors,andprioritiesforfutureresearch.Seminarsinthrombosisandhemostasis.Vol.37.7.2011,p.786-793.

6. MacutD,MicicD,SuvajdzicNetal.Ovulationinductionandearlypregnancylossinwomansusceptibletoautoimmunediseases:apossibleinterrelationship.GynecolEndiocrinol2000;14:153-7.

7. MannoM,TomeiF,FascianiA,CostaM.Ovarianhyperstimulationsyndrome:thebestapproachesforpreventionandtreatment.Amini-rewiev.

CurrWomen'sHealthRev2007;3:49-54.

5. MaraiI,CarpHJA,ShaiS,ShaboR,FishmanG,ShoenfeldY.Autoantibodypanelscreeninginrecurrentmiscarriages.AmJReprodImmunol2004;51:235-240.

6. McCartyGA.Seronegativeantibodysyndrome(SNAPS)andsnappingtoit.

Vol2.2006.

5. McNeeleyPA,DlottJS,FurieRA,JackRM,OrtelTL,TriplettDA,VictoriaEJ,LinnikMD.ß2-GlycoproteinI-dependentanticardiolipinantibodiespreferentiallybindtheaminoterminaldomainofß2-glycoproteinI.ThrombHaemost.2001;86:590–595.

6. MeroniPL,RaschiE,CameraM,TestoniC,NicolettiF,TincaniA,

KhamashtaMA,BalestrieriG,TremoliE,HessDC.EndothelialactivationbyaPL:apotentialpathogeneticmechanismfortheclinicalmanifestationsofthesyndrome.JAutoimmun.2000;15:237–240.

5. MiyakisS,LockshinMD,AtsumiT,etal.Internationalconsensusstatementonanupdateoftheclassificationcriteriafordefiniteantiphospholipidsyndrome(APS)JThrombHaemost2006;4(2):295–306.

6. MooreJE,MohrCF.Biologicallyfalsepositiveserologicaltestsforsyphilis:type, incidence, andcause.JAmMedAssoc. 1952;150:467–473.

7. MooreJE,LutzWB.Naturalhistoryofsystemiclupuserythematosus:approachtoitsstudythroughchronicbiologicfalsepositivereactors.JChronicDis.1955;1:297–316.

5. ooreHCF,TheriaultRL.Commentary:ovarianfunctiondoesnotequalfertilitydoesnotequalbabies.Oncologist2007;12:1044-54.

138. NisioM,RutjesAWS,FerranteN.Thrombophiliaandoutcomesofassistedreproductiontechnologies:asystemicreviewandmeta-analysis.Blood.2011;118:2670-2678.

139. OfosuFA.Areviewofthetwomajorregulatorypathwaysfornon-proproetarylow-molecular-weightheparins.ThrombosisandHemostasis;

107.2/2012.

138. OpatrnyL,DavidM,KahnSR,ShrierI,andReyE.Associationbetweenantiphospholipidantibodiesandrecurrentfetallossinwomenwithoutautoimmunedisease:ametaanalysis.JRheumatol2006;33(11):2214–2221.

139. OrchardE.A.,WilsonN.,OrmerodOJM.Themanagementofcryptogenicstrokeinpregnancy.ObstetricMedicine2011;4:2-6.

140. OstensenM,KhamashtaM,LockshinMetal.Anti-inflammatoryand

immunosuppresivedrugsandreproduction.ArthritisResTher2006;8:209.

138. OsturkMA,HaznedarogluIC,TurgutM,andGokerH.Currentdebatesinantiphospholipidsyndrome:theacquiredantibody-mediatedthrombophilia.ClinicalandAppliedThrombosis/Hemostasis,April1,2004;10(2):89-126.

139. QueenanJohnT.High-riskpregnancy.2007.–396p.

140. PaidasVJ,HanCS,HossainN,LockwoodCJ.Inheritedandacquiredthrombophiliainobstetrics.In:HemostasisandThrombosisinObstetricsandGynecology,1stedition.2011.67-110.

141. PalaretiG,SchellongS.Isolateddistaldeepveinthrombosis:whatweknowandwhatwearedoing.JournalofThrombosisandHemostasis, 10:11-19.

142. PassamFH,GiannakopoulosB,MirarabshahiP,KrilisSA.Molecularpathophysiologyoftheantiphospholipidsyndrome:theroleofoxidativepost-

translationalmodificationofbeta2glycoproteinI.JournalofThrombosisandHaemostasis,2011;9(Suppl.1):274-282.

138. PattisonNS,ChamleyLW,BirdsallM,ZanderigAM,LiddellHS,McDougallJ:Doesaspirinhavearoleinimprovingpregnancyoutcomeforwomenwiththeantiphospholipidsyndrome?Arandomizedcontroltrialof

treatment.Obstet. Gynecol.100, 408–413(2002).

138. PavordS,MyersB,HuntB.Antiphospholipidsyndrome.TheObstetricHematologyManual,ed.SuePavordandBeverlyHunt.2010;131-139.

139. PengoV,BiasioloA,BroccoT,TonettoS,RuffattiA.Autoantibodiestophospholipid-bindingplasmaproteinsinpatientswiththrombosisandphospholipid-reactiveantibodies.ThrombHaemost.1996;75:721–724.

140. PengoV.Antiphospholipidsyndrome:interpretationoflaboratorydata.

JournalofThrombosisandHaemostasis,2011;9(Suppl.1):402-420.

138. PengoV,BanzatoA,BisonE,BraccoA,DenasG,RuffattiA.Whatwehavelearnedaboutantiphospholipidsyndromefrompatientsandantiphospholipid

carriercohorts.SeminarsinThrombosisandHemostasis.Vol.38,N4/2012;322-325.

138. PengoV,TripodiA,ReberG,etal.Updateoftheguidelinesforlupusanticoagulantdetection.SubcommitteeonLupusAnticoagulant/AntiphospholipidAntibodyoftheScientificandStandardisationCommitteeoftheInternationalSocietyonThrombosisandHaemostasis.JThrombHaemost2009;7(10):1737–1740.

139. PengoV,RuffattiA,LegnaniC,etal.Clinicalcourseofhigh-riskpatientsdiagnosedwithantiphospholipidsyndrome.JThrombHaemost2010;8(2):237–242.

140. PengoV,RuffattiA,LegnaniC,etal.Incidenceofafirstthromboemboliceventinasymptomaticcarriersofhigh-riskantiphospholipidantibodyprofile:amulticenterprospectivestudy.Blood2011;118(17):4714–4718.

141. Pham C, Shen Y-M. Antiphospholipid antibodies and malignancy.

Hematology/OncologyclinicsofNorthAmerica.2008Elsevier.

138. PierangeliSS,HarrisEN.Invivomodelsofthrombosisfortheantiphospholipidsyndrome. Lupus.1996;5:451–455.

139. PierangeliSS,Colden-StanfieldM,LiuX,BarkerJH,AndersonGH,HarrisEN:Antiphospholipidantibodiesfromantiphospholipidsyndromepatientsactivateendothelialcellsinvitroandinvivo.Circulation99,1997–2000

(1999).

158. PierangeliSS,EspinolaRG,LiuX,HarrisEN.Thrombogeniceffectsofantiphospholipidantibodiesaremediatedbyintercellularcelladhesionmolecule-1,vascularcelladhesionmolecule-1,andP-selectin.CircRes.2001;88:245–250.

159. PorterTF.Antiphospholipidantibodiesandinfertility.ClinObstetGynecol.

2001;44:29–35.

158. PowersRW,RobertsJM,PlymireDA,PucciDetal.Lowplacentalgrowthfactoracrosspregnancyidentifiesasubsetofwomenwithpretermpreeclampsia.TypeIversusType2preeclampsia.Hypertension.Vol60,Number1, July2012,239-246.

159. QueenanJohnT.,HobbinsJohnC.,SpongC.Protocolsforhigh-riskpregnancies. //4theditionbyBlackwellPublishing.–2005.–736p.

160. QuenbyS,MountfieldS,CartwrightJE,WhitleyGS,ChamleyL,VinceG.Antiphospholipidantibodiespreventextravilloustrophoblastdifferentiation.FertilSteril2005;83:691-698.

161. RaffaellDeCaterinaandpeterLibby.Endothelialdysfunctionsandvasculardiseases.//Blackwell Publishing.–2007.–416p.

162. RandJH,WuXX,GullerS,GilJ,GuhaA,ScherJ,LockwoodCJ.

Reductionofannexin-V(placentalanticoagulantprotein-I)onplacentalvilliofwomenwithantiphospholipidantibodiesandrecurrentspontaneousabortion.AmJObstetGynecol. 1994;171:1566–1572.

158. RandJH,WuXX,AndreeHA,LockwoodCJ,GullerS,ScherJ,HarpelPC.Pregnancylossintheantiphospholipid-antibodysyndrome—apossiblethrombogenicmechanism.NEnglJMed.1997;337:154–160.

159. RandJH,WuXX,AndreeHAM,AlexanderRossJB,RosinovaE,Gascon-LemaMG,CalandriC,HarpelPC.Antiphospholipidantibodiesaccelerateplasmacoagulationbyinhibitingannexin-Vbindingtophospholipids:a"lupusprocoagulant"phenomenon.Blood.1998;92:1652–1660.

160. RandJH."Annexinopathies"—anewclassofdisease.NEnglJMed.1999;340:1035–1036.

161. RandJH,WuXX,GiesenP.Apossiblesolutiontotheparadoxofthe"lupus

anticoagulant":antiphospholipidantibodiesacceleratethrombingenerationbyinhibitingannexin-V.ThrombHaemost.1999;82:1376–1377.

158. RandJH.Theantiphospholipidsyndrome.In:BeutlerE,LichtmanMA,CollerBS,KippsTJ,SeligsohnU,eds.Williams’Hematology.6thed.New

York,NY:McGraw-Hill;2000:1715–1733.

158. RandJH,WuX-X,QuinnASetal.HumanmonoclonalantiphospholipidantibodiesdisrupttheannexinA5anticoagulantcrystalshieldonphospholipidbilayers:evidencefromatomicforcemicroscopyandfunctionalassay.Am.J.Pathol.,September1,2003;163(3):1193-1200.

159. RandJH,WuXX,QuinnAS,ChenPP,HathcockJJ,TaatjesDJ:

Hydroxychloroquinedirectlyreducesthebindingofantiphospholipid^antibody-β2^{-glycoproteinIcomplexestophospholipidbilayers.Blood112,1687}–1695(2008).

158. ReddelSW,WangYX,ShengYH,KrilisSA.Epitopestudieswithanti-ß2-glycoproteinIantibodiesfromautoantibodyandimmunizedsources.J

Autoimmun.2000;15:91–96.

158. RobertsJM,EscuderoC.Theplacentainpreeclampsia.PregnancyHypertension:AnInternationalJournalofWomen'sCardiovascularHealth2;(2012), 72-83.

159. RovenskyK:Ashersonsyndrome–catastrophicantiphospholipidsyndrome.

Autoimmun.Rev.6,61–63(2006).

158. RoubeyRA,PrattCW,BuyonJP,WinfieldJB.Lupusanticoagulantactivityofautoimmuneantiphospholipidantibodiesisdependentuponß2-glycoproteinI.JClinInvest.1992;90:1100–1104.

159. Ruiz-Irastorza,KhamashtaMA.Strokeandantiphospholipidsyndrome:thetreatmentdebate. Rheumatology2005;44:971-974.

160. RuffattiA,CalligaroA,HoxhaA,etal.Laboratoryandclinicalfeaturesofpregnantwomenwithantiphospholipidsyndromeandneonataloutcome.

ArthritisCareRes(Hoboken)2010;62(3):302–307.

158. SalmonJE,GirardiG,HolersVM:Complementactivationasamediatorofantiphospholipidantibodyinducedpregnancylossandthrombosis.Ann.Rheum. Dis.61(Suppl.2),46–50(2002).

158. SanmarcoM,SolerC,ChristidesC,etal.PrevalenceandclinicalsignificanceofIgGisotypeanti-beta2-glycoproteinIantibodiesinantiphospholipidsyndrome:acomparativestudywithanticardiolipinantibodies.JLabClinMed1997;129(5):499–506.

159. SeifAM,HwangY,PierangeliS.Managementoftheantiphospholipidsyndrome:newapproaches.Int.J.Clin.Rheumatology.2009;4(5):533-549.

160. ShapiroSS,ThiagarajanP.Lupusanticoagulants.ProgHemostThromb.

1982;6:263–285.

158. ShuF,SugimuraM,KanayamaN,KobayashiH,KobayashiT,TeraoT.ImmunohistochemicalstudyofannexinVexpressioninplacentaeofpreeclampsia. GynecolObstetInvest.2000;49:17–23.

159. SimmelinkMJ,HorbachDA,DerksenRH,MeijersJC,BeversEM,WillemsGM,deGrootPG.Complexesofanti-prothrombinantibodiesandprothrombincauselupusanticoagulantactivitybycompetingwiththebindingofclotting

factorsforcatalyticphospholipidsurfaces.Br JHaematol.2001;113:621–629.

158. SolteszP,DerH,VeresK,Lacziketal.Immunologicalfeaturesofprimaryanti-phospholipidsyndromeinconnrectionwithendothelialdysfunction.Rheumatology,November1,2008;47(11):1628-1634.

159. StefanoRaffaeleGiannubiloandAndreaLuigiTranquilli(2011).FetalThrombophilia,Thrombophilia,Prof.Prof.AndreaTranquilli(Ed.).

160. TeixeiraPG,CabralACV,AndradeSP.PlacentalGrowthFactor(PIGF)isasurrogatemarkerinpreeclamptichypertension.HypertensioninPregnancy,27:65-73, 2008.

186. TanneD,LevineSR,BreyRLetal.Antiphospholipid-proteinantibodiesandacuteischemicstrokeintheNINDSrt-PAStrokeTrial.Neurology,October28,2003;61(8):1158-1159.

187. TheEuropeanIVF-monitoringprogramme(EIM)fortheEuropeanSocietyofHumanReproductionandEmbriology(ESHRE).AssistedreproductivetechnologyinEurope,2002.ResultsgeneratedfromEuropeanregistersbyESHRE.HumReprod2006;21:1680-97.

188. TripodiA,BiasioloA,ChantarangkulV,andPengoV.Lupusanticoagulant

(LA)testing:performanceofclinicallaboratoriesassessedby anationalsurveyusinglyophilizedaffinity-purifiedimmunoglobulinwithLAactivity.ClinChem2003;49(10):1608–1614.

186. TripodiA.Tomixornottomixinlupusanticoagulanttesting?Thatisthequestion.Seminarsinthrombosisandhemostasis.Volume38,Number4/2012;385-389.

187. VanJES,EerenbergES,KamphuisenPW,BullerHR.Howtoprevent,treat,andovercomecurrentclinicalchallengesofVTE.JournalofThrombosisand

Haemostasis,2011;9(Suppl.1):265-274.

186. VanderlelieJ,PerkinsAVA.Seleniumandpreeclampsia:aglobalperspective.PregnancyHypertension:AnInternationalJournalofWomen'sCardiovascularHealth1(2011);213-224.

187. VisvanathanS,GeczyCL,HarmerJA,McNeilHP.Monocytetissuefactorinductionbyactivationofß2-glycoprotein-I-specificTlymphocytesisassociatedwiththrombosisandfetallossinpatientswithantiphospholipidantibodies.JImmunol.2000;165:2258–2262.

188. VogesD,BerendesR,BurgerA,DemangeP,BaumeisterW,HuberR.Three-dimensionalstructureofmembrane-boundannexinV:acorrelativeelectronmicroscopy-X-raycrystallographystudy.JMolBiol.1994;238:199–

213.

186. WadaH.DisseminatedIntravascularCoagulation.ClinChimActa.2004June:344(1-2):13-21.

187. WangTH,HorngSG,ChangCLetal.Humanchorionicgonadotrophin-

inducedovarianhyperstimulationsyndromeisassociatedwithupregulationofvascularendothelialgrowthfactor.JClinEndocrinolMetab2002;87:3300-8.

186. WarkentinTE,AirdWC,RandJH.Platelet-endothelialinteractions:sepsis,HIT,andantiphospholipidsyndrome.Hematology,January1,2003;2003(1):

497-519.

186. WarkentinTE.HITparadigmsandparadoxes.JournalofThrombosisandHaemostasis,2011;9(Suppl.1):105-117.

187. WeilerH.Multiplereceptor-mediatedfunctionsofactivatedproteinC.Hamostaseologie3/2011.185-193.

188. WillisR,HarrisEN,PierangeliSS.Pathogenesisoftheantiphospholipidsyndrome.SeminarsinThrombosisandHemostasis.Vol.38,N4/2012;305-317.

189. WilsonWA,GharaviAE.GeneticriskfactorsforaPLsyndrome.Lupus.

1996;5:398–403.

186. YasudaS,TsutsumiA,ChibaH,YanaiH,MiyoshiY,TakeuchiR,HoritaT,AtsumiT,IchikawaK,MatsuuraE,KoikeT.ß2-GlycoproteinIdeficiency:prevalence,geneticbackgroundandeffectsonplasmalipoproteinmetabolismandhemostasis.Atherosclerosis.2000;152:337–346.